A NOVEL COLORIMETRIC ENZYME ASSAY FOR FIBRINOLYSIS

溶栓治疗已成为一种越来越重要的工具 治疗急性心肌梗死的方法 最 最近批准的用于此目的的治疗剂是t-PA （组织纤溶酶原激活剂），其具有以下优点： 纤维蛋白特异性，并在体内被肝脏迅速清除。 的 纤溶酶的这种成分的检测和定量 系统以及其抑制剂仍然是耗时的， 通过裂解区面积测量。 我们提出了一种新的技术， 纤维蛋白溶解系统所有组分的定量 包括t-PA、纤溶酶原、纤溶酶、α 2-抗纤溶酶和 抗激活剂（例如派-1）。 该测定使用固相酶 标记的纤维蛋白作为局部产生的纤溶酶的底物。 的 激活剂和抑制剂浓度的操纵将 直接影响纤溶酶的产生量。 定量 所得纤溶酶的检测是通过检测和 释放的酶标记纤维蛋白片段的测量 通过纤溶酶的蛋白水解作用。 该测定 该技术与现有的测定相比具有许多优点 包括使用固相纤维蛋白作为底物 增强剂，其与体内情况相似。 该测定还 便于处理多个样品， 自动化，并且由于其敏感性， 有效

Thrombolytic therapy has become an increasingly important tool in the treatment of acute myocardial infarction. The most recently approved therapeutic agent for this purpose is t-PA (tissue plasminogen activator) which has the advantages of being fibrin specific and is rapidly cleared in vivo by the liver. The detection and quantitation of this component of the fibrinolytic system as well as its inhibitors is still time consuming and is measured by lysis zone areas. We propose a new technique for the quantitation of all the components of the fibrinolytic system including t-PA, plasminogen, plasmin, alpha 2-antiplasmin, and antiactivators (eg PAI-1). The assay uses a solid phase enzyme labelled fibrin as a substrate for locally generated plasmin. The manipulation of concentrations of activators and inhibitors will directly influence the amount of plasmin produced. Quantitation of the resulting plasmin is achieved through the detection and measurement of enzyme labelled fibrin fragments released through the proteolytic action of the plasmin. This assay technique has a number of advantages over existing assays including the use of solid phase fibrin as a substrate and rate enhancer which parallels the situation in vivo. The assay is also convenient for handling multiple samples, lends itself to automation and because of its sensitivity is extremely cost effective.